Search
01/05/2023
A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease
Gamez, J, Calopa, M, Munoz, E, Ferre, A, Huertas, O, McAllister, K, Reig, N, Scart-Gres, C, Insa, R, Kulisevsky, J. A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2023; 89(5)DOI:10.1111/bcp.15635. PMID:36494329. IF:3.100(Q2/4D).
01/05/2023
A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease
Kulisevsky, J, Martinez-Horta, S, Campolongo, A, Pascual-Sedano, B, Marin-Lahoz, J, Bejr-kasem, H, Labandeira-Garcia, JL, Lanciego, JL, Puig-Davi, A, Horta-Barba, A, Pagonabarraga, J, Rodriguez-Antiguedad, J. A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease. PARKINSONISM & RELATED DISORDERS. 2023; 110DOI:10.1016/j.parkreldis.2023.105367. PMID:36963339. IF:3.100(Q2/4D).
01/05/2023
EndoTrainer: a novel hybrid training platform for endoscopic surgery
Hernansanz A., Rovira R., Basomba J., Comas R., Casals A.. EndoTrainer: a novel hybrid training platform for endoscopic surgery. International Journal of Computer Assisted Radiology and Surgery. 2023; 18(5)DOI:10.1007/s11548-023-02837-x. PMID:36781742. IF:2.300(Q2/3D).
01/05/2023
Self-management interventions for adults living with obesity to improve patient-relevant outcomes: An evidence map
Sunol, R, Gonzalez-Gonzalez, AI, Valli, C, Ballester, M, Seils, L, Heijmans, M, Poortvliet, R, van der Gaag, M, Rocha, C, Leon-Garcia, M, Salas-Gama, K, de Guzman, EN, Kaloteraki, C, Santero, M, Spoiala, C, Gurung, P, Moaddine, S, Wilemen, F, Cools, I, Bleeker, J, Kancheva, A, Ertl, J, Laure, T, Kancheva, I, Veroniki, AA, Zevgiti, S, Beltran, J, Canelo-Aybar, C, Zafra-Tanaka, JH, Seitidis, G, Mavridis, D, Groene, O, Alonso-Coello, P, Orrego, C. Self-management interventions for adults living with obesity to improve patient-relevant outcomes: An evidence map. PATIENT EDUCATION AND COUNSELING. 2023; 110DOI:10.1016/j.pec.2023.107647. PMID:36739705. IF:2.900(Q2/4D).